The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 24, 2009
Filed:
Dec. 06, 2004
Jody Berry, Winnipeg Manitoba, CA;
Steven Jones, Winnipeg Manitoba, CA;
Xin Yong Yuan, Winnipeg Manitoba, CA;
Mike Gubbins, Winnipeg Manitoba, CA;
Anton Andonov, Winnipeg Manitoba, CA;
Hana Weingartl, Winnipeg Manitoba, CA;
Mike Drebot, Winnipeg Manitoba, CA;
Frank Plummer, Winnipeg Manitoba, CA;
Jody Berry, Winnipeg Manitoba, CA;
Steven Jones, Winnipeg Manitoba, CA;
Xin Yong Yuan, Winnipeg Manitoba, CA;
Mike Gubbins, Winnipeg Manitoba, CA;
Anton Andonov, Winnipeg Manitoba, CA;
Hana Weingartl, Winnipeg Manitoba, CA;
Mike Drebot, Winnipeg Manitoba, CA;
Frank Plummer, Winnipeg Manitoba, CA;
Other;
Abstract
Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.